This may be of interest to members.
The National Blood Authority (NBA) is aware of increasing off-label use of human fibrinogen concentrate (FC) for acquired hypofibrinogenaemia in Australia, partly due to the practical benefits of its storage and preparation over the comparable treatment cryoprecipitate. They are seeking your opinion through a short survey to assist them in gathering information about this.
Your feedback will provide them with understanding the real-world usage of, and interest in, the product.
The survey is anonymous and they estimate will take approximately 3 minutes. If you would like to participate, please click on this link: https://www.surveymonkey.com/r/7F556GL
The survey closes at midnight on Friday, 28 May 2021.